ACT 2025 Countdown

FEBRUARY 14

Days
:
Hrs
:
Min
:
Sec

Showcase your research at ACT 2025!

Abstract Submission: Monday, July 15, 2024 – Wednesday, October 16, 2024 at 11:59 pm (CST)

The SSO Advance Cancer Therapies Committee invites you to submit abstracts and videos for the SSO Advanced Cancer Therapies, taking place in February 14-17, 2025 at the Scott Resort & Spa, Scottsdale, AZ. All cancer care professionals, both SSO members and non-members, are strongly encouraged to submit their scientific work.

Advanced Cancer Therapies is a comprehensive forum promoting research development, education, information and networking exchanges, and the application of advanced cancer therapies.

Please review the following guidelines before submitting an abstract. To begin your submission, click the Submit button located at the bottom of this page.

KEY DATES

October 16, 2024, 11:59 PM (CST)	Abstract Submission Deadline At this time the system will close. Once submission ends, incomplete abstracts cannot be edited or submitted.
Earlty December 2024	Abstract Notification Sent to Presenter/Submitter
December 16, 2024	Abstract Author/Title Changes Deadline
February 14-17, 2025	ACT 2025 Meeting: Scottsdale, AZ

Expand All | Collapse All

General Submission Guidelines
Are there any extensions offered in the submission process? No submission extensions will be granted.
Can I edit my abstract after submission? Edits can be made to your abstract at any point prior to the closing deadline. After the closing date, edits must be sent via email and receive approval from the ACT Committee.
Is there a fee to submit my abstract? There is a non-refundable $60.00 submission fee for each abstract submitted. Fees must be paid via credit card when submitting your abstract. You will not be able to submit your abstract if the fee is not paid. Abstract fees will not be refunded if you choose to withdraw. NEW: In an effort to reduce financial burdens when submitting to both ACT25 and SSO25, all abstract submissions will receive a single-use promo code upon completing their first submission. This code can then be utilized to zero out the second meeting’s submission fee.
Is there a limit on how many abstracts I can submit? There is no restriction on the number of abstracts you may submit.
Do I have to be an SSO member to submit an abstract? You are not required to be an SSO member to submit an abstract, however, abstracts should include at least one SSO member as an author. Please contact SSO Membership at info@surgonc.org for questions.
Is there a limit on the number of authors you can add to an abstract? There is a limit of 20 co-authors per abstract.
Can I submit an abstract on behalf of a company? SSO will accept abstract submissions from authors and/or co-authors who are employees of pharmaceutical, biotechnology, or medical technology companies. Abstracts should NOT include products or lines of business.
Can I submit a case report? No, we will not accept case reports as an abstract submission.
Can I submit my abstract to the SSO 2025 Annual Meeting if I submit it to Advanced Cancer Therapies 2025 as well? Abstracts submitted to SSO 2025 can also be submitted and presented for Advanced Cancer Therapies 2025.
Do I need to register to attend the Advanced Cancer Therapies 2025? Submission of an abstract does not constitute registration for the meeting. Presenters of accepted abstracts attending the meeting are expected to register and pay the meeting registration fee. All abstract presentations will be in-person only. Registration and housing information will be available on the website in September.
Can I submit my accepted abstract into the ASO or SOI? SSO leadership believes that research presented at SSO’s annual meeting should be published in the Annals of Surgical Oncology (ASO) and the Surgical Oncology Insight (SOI), the official journals of the SSO. The following guidance provides submission information; detailed information will be provided to accepted abstract presenters. Presenters of abstracts accepted for Advanced Cancer Therapies are encouraged to submit their manuscripts to the ASO and SOI journals. Publication of all manuscripts in the journal is subject to the ASO and SOI peer review process. Detailed information will be provided after the acceptances are sent out and posted to the ACT 2025 website.
What is SSO’s Conflict of Interest policy? As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Per ACCME, there is no minimum financial threshold for financial relationships; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education. As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company. All identified conflicts of interest must be mitigated, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. Learners must be informed that all relevant financial relationships have been mitigated prior to engaging in accredited education. Learners must also be informed when off label; experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. SSO requires all learners receive disclosure information before engaging in accredited education. Disclosure to learners must include: The first and last name of individual with the financial relationship. The names of the ineligible companies with which they have relationships. The nature of the relationships. A statement that all relevant financial relationships have been mitigated. Disclosure to learners must not include ineligible companies’ corporate or product logos, trade names, or product group messages. SSO must inform learners about planners, faculty, and others in control of content (either individually or as a group) with no relevant financial relationships with ineligible companies. Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ACCME does not consider providers of clinical service directly to patients to be ineligible.
What is SSO's Copyright policy? Copyright Assignment: I represent and warrant that the attached abstract and any later-created Presentation is/will be original work. I understand that in the event my abstract is accepted by SSO, all materials related to my abstract and Presentation may by used by SSO, in any form, for educational purposes including, but not limited to, recording my oral presentation of this material; the sale of this recording; and the printing and/or electronic publication of this material, excerpts, or abstracts. I control all rights to the abstract and Presentation which is/will be created, have the authority to assign copyrights, and hereby agree to assign to SSO all copyrights in the abstract and Presentation in any medium if my abstract and Presentation is accepted by SSO.
Abstract Selection Guidelines
What happens to my abstract once the submission closes? All abstracts are subject to a blind peer-review by members of the Advanced Cancer Therapies Committee. The committee makes all final decisions relative to the abstract selection and scheduling. All reviewers, session planners and invited faculty will be required to disclose all financial relationships through the online system, helping to ensure high-quality, unbiased presentations and compliance with CME regulations. In addition, all authors must disclose all financial relationships during the submission process before their abstract will be considered and graded.
When will I be notified if my abstract has been accepted onto the program? Each abstract submitter will receive an email acknowledging receipt of the abstract after initiating a submission and after completing a submission. If the abstract is selected for inclusion during ACT 2025, the presenting author listed will receive an invitation to participate from the Program Committee by early December 2024. If the abstract is not selected, the submitting author will receive a communication regarding its decision by early December 2024. Abstracts may not be withdrawn after acceptance. You may select a replacement presenter if you are unable to present your abstract in-person. All author/title changes must be communicated prior to December 16, 2024 in order to be included in the Abstract edition of the Annals of Surgical Oncology or meeting materials. To withdraw an abstract, the presenter must notify the SSO office by the end of the abstract review. Once an abstract has been accepted for the program it may no longer be withdrawn. Prior to submitting your abstract(s), please ensure you and/or one of your team of authors has secured proper funding sources in order to present at the meeting. Presenters of the accepted abstracts must register for the meeting and are responsible for their own travel expenses as well as the meeting registration fee.
If my submission is accepted, am I required to attend ACT to present? Presenters are required to present in-person and register for ACT25.
If my submission is accepted as a Poster, how will it be presented? All accepted Poster abstracts will be electronically presented and available in the Mobile App and ACT25 website.
Can I be considered for an abstract award at ACT 2025? Through the generosity of ACPMP (Appendix Cancer/Pseudomyxoma Peritonei Research Foundation), SSO awards travel awards of $1,000 to the highest scoring abstracts in the content/research areas of appendix cancer, pseudomyxoma peritonei, peritoneal surface malignancies/peritoneal carcinomatosis, and/or HIPEC. Applicants will attest to specific criteria during submission. All abstracts will be blind-reviewed by the ACT Program Committee and recipients will be selected based on grade, abstract quality, and content relevance. Conditions: The abstract must be submitted by a resident of fellow of an ACGME accredited General Surgical residency, surgical Oncology fellowship, SSO approved Breast Surgical Oncology Fellowship Program, or Early Career Professional working with, or sponsored by, a member of the SSO. SSO defines a Resident, Fellow, or Early Career Professional as follows: Resident/Fellow: A Resident or Fellow of good standing at the time of abstract submission. If a submitter completes their residency or fellowship prior to the ACT meeting, the submitter still qualifies for award consideration. Early Career: An Early Career professional is defined as a physician who has completed their residency of fellowship within the last five (5) years. The paper must be presented by the submitter (resident, fellow, or early career professional) at ACT 2025. Winners must attend ACT 2025 in person and acknowledge ACPMP in their PowerPoint presentation.

General Submission Guidelines

Are there any extensions offered in the submission process?

No submission extensions will be granted.

Can I edit my abstract after submission?

Edits can be made to your abstract at any point prior to the closing deadline. After the closing date, edits must be sent via email and receive approval from the ACT Committee.

Is there a fee to submit my abstract?

There is a non-refundable $60.00 submission fee for each abstract submitted. Fees must be paid via credit card when submitting your abstract. You will not be able to submit your abstract if the fee is not paid. Abstract fees will not be refunded if you choose to withdraw.

NEW: In an effort to reduce financial burdens when submitting to both ACT25 and SSO25, all abstract submissions will receive a single-use promo code upon completing their first submission. This code can then be utilized to zero out the second meeting’s submission fee.

Is there a limit on how many abstracts I can submit?

There is no restriction on the number of abstracts you may submit.

Do I have to be an SSO member to submit an abstract?

You are not required to be an SSO member to submit an abstract, however, abstracts should include at least one SSO member as an author. Please contact SSO Membership at info@surgonc.org for questions.

Is there a limit on the number of authors you can add to an abstract?

There is a limit of 20 co-authors per abstract.

Can I submit an abstract on behalf of a company?

SSO will accept abstract submissions from authors and/or co-authors who are employees of pharmaceutical, biotechnology, or medical technology companies. Abstracts should NOT include products or lines of business.

Can I submit a case report?

No, we will not accept case reports as an abstract submission.

Can I submit my abstract to the SSO 2025 Annual Meeting if I submit it to Advanced Cancer Therapies 2025 as well?

Abstracts submitted to SSO 2025 can also be submitted and presented for Advanced Cancer Therapies 2025.

Do I need to register to attend the Advanced Cancer Therapies 2025?

Submission of an abstract does not constitute registration for the meeting. Presenters of accepted abstracts attending the meeting are expected to register and pay the meeting registration fee. All abstract presentations will be in-person only. Registration and housing information will be available on the website in September.

Can I submit my accepted abstract into the ASO or SOI?

SSO leadership believes that research presented at SSO’s annual meeting should be published in the Annals of Surgical Oncology (ASO) and the Surgical Oncology Insight (SOI), the official journals of the SSO. The following guidance provides submission information; detailed information will be provided to accepted abstract presenters.

Presenters of abstracts accepted for Advanced Cancer Therapies are encouraged to submit their manuscripts to the ASO and SOI journals. Publication of all manuscripts in the journal is subject to the ASO and SOI peer review process.

Detailed information will be provided after the acceptances are sent out and posted to the ACT 2025 website.

What is SSO’s Conflict of Interest policy?

As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Per ACCME, there is no minimum financial threshold for financial relationships; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education.

As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

All identified conflicts of interest must be mitigated, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. Learners must be informed that all relevant financial relationships have been mitigated prior to engaging in accredited education. Learners must also be informed when off label; experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

SSO requires all learners receive disclosure information before engaging in accredited education. Disclosure to learners must include:

The first and last name of individual with the financial relationship.
The names of the ineligible companies with which they have relationships.
The nature of the relationships.
A statement that all relevant financial relationships have been mitigated.

Disclosure to learners must not include ineligible companies’ corporate or product logos, trade names, or product group messages.

SSO must inform learners about planners, faculty, and others in control of content (either individually or as a group) with no relevant financial relationships with ineligible companies.

Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ACCME does not consider providers of clinical service directly to patients to be ineligible.

What is SSO's Copyright policy?

Copyright Assignment: I represent and warrant that the attached abstract and any later-created Presentation is/will be original work. I understand that in the event my abstract is accepted by SSO, all materials related to my abstract and Presentation may by used by SSO, in any form, for educational purposes including, but not limited to, recording my oral presentation of this material; the sale of this recording; and the printing and/or electronic publication of this material, excerpts, or abstracts. I control all rights to the abstract and Presentation which is/will be created, have the authority to assign copyrights, and hereby agree to assign to SSO all copyrights in the abstract and Presentation in any medium if my abstract and Presentation is accepted by SSO.

Abstract Selection Guidelines

What happens to my abstract once the submission closes?

All abstracts are subject to a blind peer-review by members of the Advanced Cancer Therapies Committee. The committee makes all final decisions relative to the abstract selection and scheduling.

All reviewers, session planners and invited faculty will be required to disclose all financial relationships through the online system, helping to ensure high-quality, unbiased presentations and compliance with CME regulations. In addition, all authors must disclose all financial relationships during the submission process before their abstract will be considered and graded.

When will I be notified if my abstract has been accepted onto the program?

Each abstract submitter will receive an email acknowledging receipt of the abstract after initiating a submission and after completing a submission. If the abstract is selected for inclusion during ACT 2025, the presenting author listed will receive an invitation to participate from the Program Committee by early December 2024. If the abstract is not selected, the submitting author will receive a communication regarding its decision by early December 2024.

Abstracts may not be withdrawn after acceptance. You may select a replacement presenter if you are unable to present your abstract in-person. All author/title changes must be communicated prior to December 16, 2024 in order to be included in the Abstract edition of the Annals of Surgical Oncology or meeting materials.

To withdraw an abstract, the presenter must notify the SSO office by the end of the abstract review. Once an abstract has been accepted for the program it may no longer be withdrawn. Prior to submitting your abstract(s), please ensure you and/or one of your team of authors has secured proper funding sources in order to present at the meeting. Presenters of the accepted abstracts must register for the meeting and are responsible for their own travel expenses as well as the meeting registration fee.

If my submission is accepted, am I required to attend ACT to present?

Presenters are required to present in-person and register for ACT25.

If my submission is accepted as a Poster, how will it be presented?

All accepted Poster abstracts will be electronically presented and available in the Mobile App and ACT25 website.

Can I be considered for an abstract award at ACT 2025?

Through the generosity of ACPMP (Appendix Cancer/Pseudomyxoma Peritonei Research Foundation), SSO awards travel awards of $1,000 to the highest scoring abstracts in the content/research areas of appendix cancer, pseudomyxoma peritonei, peritoneal surface malignancies/peritoneal carcinomatosis, and/or HIPEC.

Applicants will attest to specific criteria during submission. All abstracts will be blind-reviewed by the ACT Program Committee and recipients will be selected based on grade, abstract quality, and content relevance.

Conditions:

The abstract must be submitted by a resident of fellow of an ACGME accredited General Surgical residency, surgical Oncology fellowship, SSO approved Breast Surgical Oncology Fellowship Program, or Early Career Professional working with, or sponsored by, a member of the SSO. SSO defines a Resident, Fellow, or Early Career Professional as follows:
- Resident/Fellow: A Resident or Fellow of good standing at the time of abstract submission. If a submitter completes their residency or fellowship prior to the ACT meeting, the submitter still qualifies for award consideration.
- Early Career: An Early Career professional is defined as a physician who has completed their residency of fellowship within the last five (5) years.
The paper must be presented by the submitter (resident, fellow, or early career professional) at ACT 2025.
Winners must attend ACT 2025 in person and acknowledge ACPMP in their PowerPoint presentation.

Abstract submissions are now closed.

Notifications will be sent out in early-December. If you have any questions, please contact SSO Meetings & Education Department at advancedtherapies@surgonc.org.